Search

Narrow Results
Search
Use my current location
Search

Tag

Number of results found: 7
Use this additional navigation to go to the next pages. Use tab and enter keyboard keys to navigate the menu 1 Page 1 of 1
Skipped to 7 results found. Page 1 of 1
    • Tuesday, Apr 20, 2021

    Researchers at Renown Seek Convalescent Plasma Study Participants

    Physician researchers seek to understand how the immune system responds to COVID-19 and create a healthier Nevada. During the early stages of the pandemic, convalescent plasma was considered the only viable treatment option available for patients with COVID-19. Convalescent plasma is the component of the blood from recovered patients that may contain COVID-19 antibodies that help fight the infection. The National Institutes of Health has since developed treatment guidelines for COVID-19 based on clinical trial data and many studies are still underway worldwide assessing various additional treatment options. Convalescent plasma was in high demand but difficult to locate for COVID-19 patients in the northern Nevada area. A 24-year-old nursing assistant, Austin Meegan, was hospitalized and spent weeks staving off kidney and lung failure before learning he was eligible for an experimental blood transfusion that showed promise in treating COVID-19. Doctors estimated Meegan had only about a 3% chance of tracking down a donor to match his rare blood type. A COVID-19 survivor, Thomas Gibson, a Texas resident with the same blood type, traveled to Reno to donate his viral antibodies and a convalescent plasma donation credited with helping to save Meegan’s life. Physician clinical researchers and scientists at Renown and the University of Nevada, Reno School of Medicine (UNR Med) knew they needed to create better options for patients and physicians. Clinical researchers developed a study to help other patients like Austin, and pleaded for donations from recovered COVID-19 patients to donate their convalescent plasma. The researcher teams looked to understand how the body’s immune system responds to the virus over time, to aid them in developing new treatments for COVID-19. “The world’s capacity to get through the COVID crisis will depend on four things — science, technology, innovation and partnerships, says Tony Slonim, MD, DrPH, President and CEO of Renown Health.  “Taking lab bench discoveries to the bedside of patients in an efficacious and timely manner is not easy, but with UNR Med and our partners, we are making great strides in advancing clinical research which has the power to save lives and to create a healthier Nevada.” “It’s tremendously promising to partner on clinical research that will not only help us better understand the disease, but help inform treatment for those combatting COVID-19 that has had such a devastating impact on Nevadans, our nation and the world,” says UNR Med Dean Thomas L. Schwenk, MD. Renown, UNR Med and other area health care partners collaborated with Vitalant to collect plasma from recovered donors for a study on the treatment's efficacy. Eligible donors are at least 18 years old, weigh more than 110 pounds and are healthy. Donors had fully recovered from a confirmed diagnosis of COVID-19. Project coordinators at the Renown Research Office were overwhelmed by the community’s support and plasma blood donations. Additional partnerships with the Washoe County Health District, the State of Nevada and the Governor’s office, Saint Mary’s Medical Center, Northern Nevada Medical Center, Carson Tahoe Health and the VA Sierra Nevada Health Care System, along with many area health care providers helped the team meet their goals of enrolling 120 eligible participants in the study. “Our success in this study rests heavily on the support of our great community, as well as the innovation and collaboration demonstrated by Renown and UNR Med,” said Sara Healy, MD, MPH, principal investigator of the study and a pediatric infectious disease physician at Renown Children’s Hospital and UNR Med. “We are proud to be at the forefront of conducting essential research during such a pivotal time in history, and look forward to our continued partnership as we continue this important work.” “The control of COVID-19 in our communities relies on testing. The study that is being launched to develop a sensitive, specific and easier way to collect specimens (blood) is advancing the field and brings promise towards getting to our common goal of having the right diagnostic test for the right clinical situation at the right time,” says Mark Riddle, MD, DrPH, FISTM, associate investigator of the study and associate dean for clinical research and professor at UNR Med's Department of Internal Medicine and Medical Research. The research team is now asking area residents to participate in a study to analyze the efficacy of two COVID-19 tests. Participants will undergo two blood tests: one being a finger stick to provide results for a rapid test, and the other is a traditional venipuncture draw confirming the presence or absence of COVID-19 antibodies. This study is a collaboration with InBios International, Inc., a leading biotechnology company based in Seattle. Researchers are seeking: Individuals who have confirmed positive for COVID-19 and who have recently recovered from the virus. Study participants must be within 7-28 days from the onset of their symptoms. Individuals who have recently tested negative for COVID-19 and have never tested positive. Those who are interested in participating in the study may contact project coordinators at the Renown Research Office at (775) 982-3646, or via e-mail at covidplasmascreening@renown.org, 7:30 A.M. – 5:00 P.M., Monday through Friday. Individuals aged 18-75 in general good health are encouraged to consider participating in this ongoing study. There is no cost to participate in this study and participation is voluntary. An individual’s decision to participate will not affect their current or future relations with their health care provider(s), health district, or the community. Those who decide to participate are free to withdraw at any time. “Time is of the essence with COVID. If we can get test results to people and their clinicians in a more timely way, we can make a faster diagnosis of a patient's condition, says Christopher M. Kozlowski, MD, MHA, Renown's institutional research officer and Medical Director/VP of Renown Institute for Heart & Vascular Health. “As we refine the accuracy of our testing; we are applying sensitivity and specificity testing for true negative and true positive results. This provides people with more timely and accurate results and better quality care.”     About Renown Health Renown Health is a locally governed, not-for-profit integrated healthcare network serving northern Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown has a long tradition and commitment to improve the care and the health of our community.     About the University of Nevada, Reno School of Medicine The University of Nevada, Reno School of Medicine (UNR Med), Nevada’s first medical school, is a community-based, research-intensive medical school with a statewide vision for a healthy Nevada. Established in 1969, UNR Med is improving the health and well-being of all Nevadans and their communities through excellence in student education, postgraduate training and clinical care, research with local, national and global impact and a culture of diversity and inclusion. For more information, visit med.unr.edu.

    Read More About Researchers at Renown Seek Convalescent Plasma Study Participants

    • Wednesday, Oct 04, 2023

    Saving More Lives; Renown Expands Breast Cancer Care, Adding Two Best-In-Class Breast Surgeons

    Renown Medical Group is thrilled to welcome two distinguished breast surgical oncologists, Colleen O'Kelly Priddy, MD and Michelle K. Chu, MD to the team. These highly skilled breast surgeons will solely focus on providing breast care and therefore play a pivotal role in Renown Health’s William N. Pennington Cancer Institute’s commitment to provide subspecialized care to the people living in our community and beyond. Dr. Colleen O'Kelly Priddy is a fellowship-trained, board-certified breast surgical oncologist with an impressive background in breast cancer surgery. Dr. Priddy was born at Washoe Medical Center (which later became Renown Regional Medical Center) and grew up in Susanville, CA before attending Stanford University for her undergraduate studies. She is a graduate of the University of Nevada, Reno School of Medicine. "I am thrilled to return to Reno to help increase access to world-class surgical breast cancer care,” said Dr. Priddy. “My focus is to provide exceptional care, particularly for young people with breast cancer. I am excited to continue my mission here in northern Nevada." Dr. Michelle K. Chu, a board-certified general surgeon, brings her extensive experience in advanced breast cancer treatment to the Renown team. Dr. Chu received her undergraduate degree from the University of Pennsylvania and her medical degree from Western Reserve School of Medicine in Cleveland, OH. Dr. Chu specializes in oncoplastic breast conserving surgery and nipple sparing mastectomies. "I believe in tailoring treatment options to each patient's unique needs,” Dr. Chu said. “Whether it's preserving the natural shape of the breast or supporting the 'Going Flat' movement, our team strives to provide the best possible outcome for every patient." The newest addition to the William N. Pennington Cancer Institute, Renown Breast Surgery Care provides comprehensive breast surgery care at 1500 E. 2nd Street in Reno, adjacent to the Renown Regional Medical Center campus. "Breast cancer accounts for approximately 20% of newly diagnosed cancer cases in Washoe County, with roughly 520 new cases annually, establishing it as the most prevalent cancer type within our community,” says Brian Erling, MD, MBA, President & CEO, Renown Health. “We are proud, as the community’s largest not-for-profit healthcare system, to invest in cancer prevention and early diagnoses, including mammography screening and genetic research. For those diagnosed with breast cancer, Renown now offers two superb breast surgeons specializing in breast preservation surgery, and a breast surgery center providing comprehensive, compassionate care. Our goal is to save women’s lives, save families and ensure better care and better outcomes. This is a major step forward for women’s healthcare and our community.” As part of this expansion, Renown is assuming operations of Reno Surgical Advocates, a respected private practice in Reno. "Access to expert breast cancer care close to home is crucial, and our dedicated team at Renown Breast Surgery Care will work tirelessly to provide the highest level of care to patients while working closely with our other cancer specialists," said Max Coppes, MD, PhD, MBA, Director, William N. Pennington Institute for Cancer. “With the exceptional expertise of Dr. Colleen O'Kelly Priddy and Dr. Michelle K. Chu, coupled with our state-of-the-art facility; Renown Health is a true partner in the fight against breast cancer in northern Nevada.” "People are increasingly relocating to northern Nevada, and in fact, Washoe County experienced a 2.1% population growth from April 2020 to July 2022. Consequently, although northern Nevada does not exhibit an above-average cancer rate, we are observing a rise in cases at our facilities," said Dr. Lee Schwartzberg, MD, FACP, Section Chief of Medical Oncology at the William N. Pennington Cancer Institute. "Renown Health is positioned to meet this growing demand, and we take pride in consistently adding nationally renowned healthcare providers to our team to save the lives of women in northern Nevada. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health.

    Read More About Saving More Lives; Renown Expands Breast Cancer Care, Adding Two Best-In-Class Breast Surgeons

    • Cancer Care
    • Mammogram
    • Screening

    Ladies! Get Screened for Breast Cancer

    Early detection is a significant piece of the breast cancer puzzle. Susan Cox, Renown Health Director of Cancer Operations, discusses what you need to watch for and how the latest technology can help detect potential cancer sooner. When should women start getting breast exams? It depends on risk factors: Average-risk women: Most medical organizations recommend the first mammogram between 40 and 44. Higher-risk women: Dependent on their high risk, which will dictate when they start screening, but generally around the age of 30 and not before 25 years old.

    Read More About Ladies! Get Screened for Breast Cancer

    • HealthyNV Project
    • Research and Studies
    • Mammogram
    • Genetic
    • Cancer Care

    Optimizing Mammogram Screenings: A Genetic Approach to a Personalized Screening Schedule

    Breast cancer screening has long been a cornerstone of women's healthcare. With 1 in 8 women diagnosed with breast cancer in their lifetime1, the United States Preventive Services Task Force (USPSTF) has developed screening recommendations to help detect early-stage cancer. Notably in 2023, the USPSTF revised the recommended age for biennial mammogram screenings for women with average risk to start at age 40 instead of 502, estimated to result in 19% more lives being saved3 by starting screening earlier. While initiating screening at an earlier age offers advantages to a wide demographic, concerns about the potential of over-screening prompted research into the feasibility of identifying women with lower breast cancer risk who could safely delay mammograms. While guidelines address high-risk individuals, a notable gap exists in providing recommendations tailored to those at lower risk. To gain insight into a patient's risk level, physicians are able to utilize genetic testing to understand an individual's genetic makeup, providing precise insights into their predisposition to various health conditions, including breast cancer. Armed with this genetic information, healthcare providers could craft tailored screening strategies that align with an individual’s specific risk profile. This genetic risk-based approach underscores the value of genetics in individualizing the onset of screening to help avoid over-screening and its associated costs. Surprisingly, genetic information is not currently being widely utilized to identify women at risk of breast cancer or other diseases in clinical practice, despite its potential to make a significant positive impact for patients. A recent retrospective analysis of 25,591 women from the Healthy Nevada Project4 sheds light on the potential benefits of this genetic risk-based approach. The study classified 2,338 (9.1%) of these women as having a low genetic risk for breast cancer. What's remarkable is that these women exhibited a significantly lower and later onset of breast cancer compared to their average or high-risk counterparts. This finding suggests that it might be safe for low-risk women to delay mammogram screening by 5 to 10 years without compromising their health.

    Read More About Optimizing Mammogram Screenings: A Genetic Approach to a Personalized Screening Schedule

    • Women's Health
    • Mammogram

    The Facts About Menopause and Early Menopause

    Menopause is something that every woman experiences at some point in her lifetime. Learn what to expect and how you can help manage the symptoms and health risks. Most women don’t experience menopause until their 50s, but certain factors such as chromosomal abnormalities, glandular problems and chemotherapy can cause early menopause before the age of 40. No matter what your age, it’s a good idea be aware of the risks and treatments available to maintain a comfortable and healthy lifestyle. Health Risks of Menopause Two of the biggest health risks posed to women who have gone through menopause are bone density loss and risk of cardiovascular disease. Bone loss can be treated with bisphosphonate and estrogens. “Calcium with vitamin D and weight bearing exercise will also limit bone loss,” says Vickie Tippett, MD and OB/GYN at Renown Health. For cardiovascular risk, a healthy lifestyle is key. Discontinuing tobacco use, getting regular exercise and maintaining a healthy weight and diet all help reduce a woman’s risk of cardiovascular disease. Managing Discomforts of Menopause One of the most common complaints about menopause is the discomfort of hot flashes. “Hot flashes can be treated with systemic estrogen alone or in combination with progesterone or another agent similar to estrogen,” Dr. Tippett says. “Non-hormonal medications such as SSRIs and antidepressants also work.” Vaginal dryness, another common symptom of menopause, can also be treated with estrogen, estrogen-like compounds and personal lubricants. Pills, patches, creams and many other formulations are available to help alleviate discomfort. Knowing when, why and what to expect when it comes to menopause can help make the transition easier. Learn the facts about menopause in the infographic below.

    Read More About The Facts About Menopause and Early Menopause

    • Women's Health
    • Mammogram

    What Every Woman Needs to Know About Dense Breast Tissue

    In honor of International Women’s Day, we’re working to spread the word about taking care of your breast health and encouraging the women in your life to do the same.  Heather Reimer is on a mission — a mission to educate women everywhere about breast tissue type. For women with dense breasts, knowing your breast tissue type is absolutely critical, as cancers embedded in dense breast tissue are not always detectable with a mammogram alone. Dense breast tissue requires a breast ultrasound screening to get a complete breast health picture. Whole Breast Ultrasound for Dense Breast Tissue Heather knows this firsthand. She has dense breasts, and in this video she shares her story about finding breast cancer during a breast ultrasound screening — cancer that went undetected with her mammogram screening alone. As a result of that experience, Heather founded Each One. Tell One. — a movement to encourage women to pass along this information to others and to prompt those with dense breast and implants to consult with their doctor to schedule a whole breast ultrasound screening. To schedule a mammogram or a whole breast ultrasound, call 775-982-8100.

    Read More About What Every Woman Needs to Know About Dense Breast Tissue

    • Cancer Care
    • Mammogram
    • Screening

    3D vs Whole Breast Ultrasound Which is Right for You

    Breast cancer is the leading cause of cancer deaths in women in the U.S. That’s why early detection is so important. Dr. George Krakora, a radiologist with Renown Institute for Cancer, explains what to watch for and how new technology can lead to early detection. Most women know the importance of breast health and staying current with annual breast exams, but may not know that both screening guidelines and technology is evolving. So we asked George Krakora, MD, a radiologist for the Renown Institute for Cancer, what every woman should know about breast cancer detection and which screening method is right for them. First off, when should women start getting breast exams? Generally, women should start getting breast exams using mammography or ultrasound after they turn 40 years old. But we also want women ages 18 to 39 to talk to their primary care provider and ask for what’s called a formal risk assessment to see if screening is needed sooner. And you want to make sure your care provider is giving you a breast exam starting at age 25. It’s also a good idea to be familiar with how your breasts look and feel so you can report any changes to your care provider. What are the risk factors for breast cancer? Are there any preventive steps women can take? There a few risk factors you can’t control, like your age, family history of breast or other cancers, and if you have dense breast tissue. Your risk for breast cancer increases as you get older, and most breast cancers are diagnosed after age 50. Knowing your family history is important because a history of cancer and shared lifestyle can raise your risk. Your breast density can also increase your risk: Women with high breast density are four-to-five times more likely to get breast cancer than women with low breast density. But the good news is there are quite a few things you can do to prevent breast cancer, like not smoking, watching your alcohol intake, and maintaining a healthy weight with good diet and exercise. There are a lot of newer screenings out today. What is the difference between 2-D and 3-D mammography? In a 2-D mammogram, the tech takes X-rays of the breast. These pictures can show the radiologist if there are any lumps or tumors you might not be able to feel. In 3-D mammography, the process is largely the same but more X-rays are taken and it takes a few seconds longer for each image. This kind of exam detects 41 percent more cancers and reduces the number of false-positive results given to patients. This improvement in technology is great for both patients and their care providers. 3-D mammography provides better images of the breast, which allow doctors to more clearly diagnose and avoid false positives, especially in women with dense breast tissue. And what about a whole breast ultrasound. What is that? A whole breast ultrasound uses sound waves to detect cancerous tumors in the breast without using any radiation — it’s an ultrasound just like pregnant women get to check up on their baby. And the exam only takes about 20 minutes. We recommend these exams for patients whose mammograms have shown that they have dense breast tissue. Dense breast tissue can make it harder for doctors to see any abnormalities, lumps or tumors in a mammogram, so this technology ensures better early detection.

    Read More About 3D vs Whole Breast Ultrasound Which is Right for You

Number of results found: 7
Use this additional navigation to go to the next pages. Use tab and enter keyboard keys to navigate the menu 1 Page 1 of 1
Skipped to 7 results found. Page 1 of 1